Top Page
China Resources Pharmaceutical Group Ltd.
(3320)
China Resources Pharmaceutical Group Ltd. (3320) vs. iShares MSCI Hong Kong ETF (EWH)
China Resources Pharmaceutical Group Ltd. Business Overview & Revenue Model
China Resources Pharmaceutical Group Ltd. Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 281.84B | 274.18B | 270.40B | 254.11B | 236.81B | 200.42B |
| Gross Profit | 44.59B | 43.30B | 42.18B | 39.13B | 35.38B | 32.29B |
| EBITDA | 15.71B | 15.45B | 15.43B | 15.47B | 11.95B | 12.47B |
| Net Income | 3.07B | 3.57B | 3.85B | 3.50B | 3.08B | 2.78B |
Balance Sheet | ||||||
| Total Assets | 314.32B | 274.28B | 271.48B | 243.93B | 248.56B | 209.37B |
| Cash, Cash Equivalents and Short-Term Investments | 34.54B | 17.48B | 59.27B | 32.52B | 37.32B | 52.34B |
| Total Debt | 90.96B | 73.43B | 62.16B | 63.85B | 67.96B | 55.20B |
| Total Liabilities | 191.56B | 169.90B | 169.20B | 150.24B | 152.69B | 128.69B |
| Stockholders Equity | 54.75B | 51.34B | 50.60B | 49.56B | 50.98B | 46.47B |
Cash Flow | ||||||
| Free Cash Flow | 17.88B | 14.55B | 12.42B | 7.54B | 8.32B | 4.06B |
| Operating Cash Flow | 21.15B | 17.55B | 15.55B | 10.90B | 11.22B | 6.28B |
| Investing Cash Flow | -8.37B | -8.89B | -2.07B | -3.30B | -8.83B | -2.02B |
| Financing Cash Flow | -13.39B | -16.84B | -4.07B | -9.00B | 5.31B | -3.60B |
China Resources Pharmaceutical Group Ltd. Technical Analysis
China Resources Pharmaceutical Group Ltd. Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
75 Outperform | HK$43.56B | 9.45 | 7.86% | 7.15% | 1.13% | -13.53% | |
73 Outperform | HK$28.04B | 13.30 | 12.65% | 3.13% | 10.56% | -13.58% | |
71 Outperform | HK$33.02B | 11.63 | 14.91% | 4.09% | -0.45% | 9.00% | |
68 Neutral | HK$29.09B | 9.57 | 5.90% | 2.95% | ― | ― | |
65 Neutral | HK$34.23B | 19.13 | 10.01% | 2.26% | 11.78% | 19.06% | |
53 Neutral | HK$78.43B | 16.54 | 6.75% | 1.69% | -1.12% | 76.16% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
China Resources Pharmaceutical Group Ltd. Corporate Events
China Resources Pharmaceutical Group Limited has announced a delay in sending to shareholders a circular related to its sales framework agreement for 2026–2028 with China Resources Healthcare Group Limited. The circular, which will include details of the agreement, proposed annual caps, independent board and financial adviser opinions, and notice of an extraordinary general meeting, was originally expected within 15 business days of a 16 December 2025 announcement but will now be dispatched on or before 15 January 2026 to allow more time to prepare and finalise the required information under Hong Kong listing rules.
The most recent analyst rating on (HK:3320) stock is a Hold with a HK$5.50 price target. To see the full list of analyst forecasts on China Resources Pharmaceutical Group Ltd. stock, see the HK:3320 Stock Forecast page.
China Resources Pharmaceutical Group Ltd. has arranged for its subsidiary CR Sanjiu Chenzhou to continue sourcing energy for heating and cooling, steam and electricity from CR Gas Chenzhou, an indirect wholly owned subsidiary of China Resources Gas, to support its Southern China manufacturing centre from 1 January 2026 to 31 December 2028 under a new framework agreement. Because both CR Pharmaceutical and CR Gas share a common controlling shareholder, the renewed energy purchase arrangement is classified as a continuing connected transaction under Hong Kong listing rules, triggering reporting, announcement and annual review requirements but exempting it from independent shareholders’ approval, thereby formalising a key utility supply relationship while keeping compliance obligations relatively light.
The most recent analyst rating on (HK:3320) stock is a Hold with a HK$5.50 price target. To see the full list of analyst forecasts on China Resources Pharmaceutical Group Ltd. stock, see the HK:3320 Stock Forecast page.
China Resources Pharmaceutical Group has completed the regulatory registrations and industry association filings required to establish a new private investment fund in mainland China, securing a filing record from the Asset Management Association of China. The fund will be managed by Shenzhen CR Capital, an experienced AMAC-licensed private fund manager with a track record across pharmaceuticals, healthcare and other high-tech sectors, and CR Pharm (Shantou), a wholly owned subsidiary of the Group, will serve as a general and executive partner actively involved in daily management, project sourcing and post-investment cooperation. The fund is expected to invest in synthetic biology, innovative drugs and biotechnology and, although accounted for as an equity investment, is intended to connect the Group with key companies, products, policy support and industrial resources in Hohhot’s emerging synthetic biology ecosystem, supporting the Group’s strategy to build a synthetic biology industrialization platform and deepen its presence in cutting-edge life science technologies.
The most recent analyst rating on (HK:3320) stock is a Hold with a HK$5.50 price target. To see the full list of analyst forecasts on China Resources Pharmaceutical Group Ltd. stock, see the HK:3320 Stock Forecast page.
China Resources Pharmaceutical Group Ltd. has entered into a supplemental framework agreement with its controlling shareholder, China Resources (Holdings) Co. Ltd. (CR Holdings), under which the CR Holdings Group will continue to lease properties and provide property management services, including cleaning and security, to the pharmaceutical group from 1 January 2026 to 31 December 2028. The transactions, conducted on normal commercial terms and priced with reference to market conditions and property characteristics, are classified as continuing connected transactions under Hong Kong’s Listing Rules; because the relevant percentage ratios fall between 0.1% and 5%, they are subject to reporting, announcement and annual review requirements but are exempt from independent shareholders’ approval, ensuring regulatory compliance while securing operational premises and services for the group’s ongoing business needs.
The most recent analyst rating on (HK:3320) stock is a Hold with a HK$5.50 price target. To see the full list of analyst forecasts on China Resources Pharmaceutical Group Ltd. stock, see the HK:3320 Stock Forecast page.
China Resources Pharmaceutical Group Ltd. has announced the signing of a new Sales Framework Agreement with CR Healthcare, effective from January 1, 2026, to December 31, 2028. This agreement, which involves connected transactions due to the relationship between the companies, requires approval from independent shareholders as the applicable percentage ratios exceed 5%. An Extraordinary General Meeting (EGM) will be convened to seek this approval, and a circular detailing the agreement will be dispatched to shareholders.
The most recent analyst rating on (HK:3320) stock is a Hold with a HK$5.50 price target. To see the full list of analyst forecasts on China Resources Pharmaceutical Group Ltd. stock, see the HK:3320 Stock Forecast page.
China Resources Pharmaceutical Group Ltd. and CR Medical Group have entered into a new Cooperation Framework Agreement for 2026/2028 to continue their collaboration on supply chain management services. This agreement aims to enhance the efficiency and reduce costs of CR Pharmaceutical’s medical supplies supply chain, with CR Medical receiving management service fees. The transactions under this agreement are considered continuing connected transactions and are subject to certain reporting and review requirements under the Listing Rules.
The most recent analyst rating on (HK:3320) stock is a Hold with a HK$5.50 price target. To see the full list of analyst forecasts on China Resources Pharmaceutical Group Ltd. stock, see the HK:3320 Stock Forecast page.
China Resources Pharmaceutical Group Ltd. has announced the successful issuance of the first tranche of its Medium Term Notes 2025, amounting to RMB3 billion with a 3-year term and a coupon rate of 2.19% per annum. The proceeds from this issuance will be used to repay interest-bearing debt, potentially strengthening the company’s financial position and operational flexibility.
The most recent analyst rating on (HK:3320) stock is a Hold with a HK$5.50 price target. To see the full list of analyst forecasts on China Resources Pharmaceutical Group Ltd. stock, see the HK:3320 Stock Forecast page.
China Resources Pharmaceutical Group Ltd. has entered into new Framework Loan Agreements for the period from January 1, 2026, to December 31, 2028, with CRI and CR Holdings, both of which are connected entities to the company. These agreements, which replace the expiring 2023 agreements, are part of the company’s ongoing financial arrangements and are subject to reporting and annual review requirements but do not require independent shareholder approval due to the size of the transactions.
The most recent analyst rating on (HK:3320) stock is a Hold with a HK$5.50 price target. To see the full list of analyst forecasts on China Resources Pharmaceutical Group Ltd. stock, see the HK:3320 Stock Forecast page.
China Resources Pharmaceutical Group Ltd. announced a change in its company secretary and authorized representative, effective December 15, 2025. Ms. Cheng Kwai Yuk resigned from her roles, with no disagreements with the board, and Ms. Wan Wing Yi Carol, who has extensive experience in corporate secretarial services, has been appointed as her successor. This transition is expected to maintain the company’s governance standards and ensure continued compliance with Hong Kong Stock Exchange regulations.
The most recent analyst rating on (HK:3320) stock is a Hold with a HK$5.50 price target. To see the full list of analyst forecasts on China Resources Pharmaceutical Group Ltd. stock, see the HK:3320 Stock Forecast page.
China Resources Pharmaceutical Group Ltd. has entered into the Amended Business Travel Services Framework Agreement 2026 with CR Digital, a wholly-owned subsidiary of its controlling shareholder, CRI. This agreement, effective from December 10, 2025, to December 31, 2027, replaces the previous 2025 agreement and outlines the use of CR Digital’s online business travel platform for various services. The transactions under this agreement are classified as continuing connected transactions, requiring reporting and annual review but exempt from independent shareholders’ approval due to their percentage ratios.
The most recent analyst rating on (HK:3320) stock is a Hold with a HK$5.50 price target. To see the full list of analyst forecasts on China Resources Pharmaceutical Group Ltd. stock, see the HK:3320 Stock Forecast page.
China Resources Pharmaceutical Group Ltd. announced that its subsidiary, CR Pharmaceutical Commercial, has received approval from the National Association of Financial Market Institutional Investors to issue medium term notes in China. The registration allows for the issuance of up to RMB3 billion in notes over two years, with proceeds intended for repaying interest-bearing debt, potentially impacting the company’s financial stability and market positioning.
The most recent analyst rating on (HK:3320) stock is a Hold with a HK$5.50 price target. To see the full list of analyst forecasts on China Resources Pharmaceutical Group Ltd. stock, see the HK:3320 Stock Forecast page.
China Resources Pharmaceutical Group Ltd. has announced proposed amendments to its Articles of Association, aiming to align with the latest legal and regulatory requirements concerning treasury shares and shareholder communication. These changes are subject to shareholder approval at an upcoming extraordinary general meeting, reflecting the company’s commitment to compliance and operational transparency.
The most recent analyst rating on (HK:3320) stock is a Hold with a HK$5.50 price target. To see the full list of analyst forecasts on China Resources Pharmaceutical Group Ltd. stock, see the HK:3320 Stock Forecast page.
China Resources Pharmaceutical Group Ltd. has successfully completed the public issuance of the second tranche of its 2025 Corporate Bonds in the PRC, raising RMB1.1 billion. The proceeds will be utilized for various operational expenses, including debt repayment, working capital replenishment, and investments in scientific and technological innovations, which may strengthen the company’s financial position and support its growth initiatives.
The most recent analyst rating on (HK:3320) stock is a Hold with a HK$5.50 price target. To see the full list of analyst forecasts on China Resources Pharmaceutical Group Ltd. stock, see the HK:3320 Stock Forecast page.
China Resources Pharmaceutical Group Ltd. has announced the formation of a new fund with a proposed size of RMB500 million, aimed at investing in high-growth enterprises in synthetic biology, innovative drugs, and biotechnology. The company’s subsidiaries, CR Pharm (Shantou), CR Double-Crane, and CR Pharmaceutical Investment, will collectively contribute RMB123 million, representing 24.6% of the total capital commitment. The fund will not be considered a subsidiary of the company, and Shenzhen CR Capital will manage it. This move is a connected transaction under the Hong Kong Listing Rules, due to the involvement of Hanwei Huayou Shantou, a connected person of the company.
The most recent analyst rating on (HK:3320) stock is a Hold with a HK$5.50 price target. To see the full list of analyst forecasts on China Resources Pharmaceutical Group Ltd. stock, see the HK:3320 Stock Forecast page.
CR Boya Bio-pharmaceutical, a subsidiary of China Resources Pharmaceutical Group, reported its unaudited financial results for the nine months ending September 30, 2025. The company experienced a revenue increase to RMB 1.47 billion compared to the previous year, but net profit decreased to RMB 343 million. Additionally, there was a significant reduction in cash and cash equivalents, highlighting potential liquidity challenges. The financials, prepared under PRC accounting standards, have not been audited and may be subject to adjustments, urging caution among shareholders and investors.
The most recent analyst rating on (HK:3320) stock is a Hold with a HK$5.50 price target. To see the full list of analyst forecasts on China Resources Pharmaceutical Group Ltd. stock, see the HK:3320 Stock Forecast page.
CR Sanjiu reported its unaudited financial results for the nine months ending September 30, 2025, showing a revenue increase to RMB 21.99 billion from RMB 19.74 billion in the previous year, despite a decline in net profit to RMB 2.90 billion from RMB 3.24 billion. The financials highlight a net decrease in cash and cash equivalents and a significant rise in total assets and liabilities, indicating potential adjustments during auditing, and advising caution for shareholders and investors.
The most recent analyst rating on (HK:3320) stock is a Hold with a HK$5.50 price target. To see the full list of analyst forecasts on China Resources Pharmaceutical Group Ltd. stock, see the HK:3320 Stock Forecast page.
Jiangzhong Pharmaceutical, a subsidiary of China Resources Pharmaceutical Group, reported its unaudited financial results for the nine months ending September 30, 2025. The company saw a slight decrease in revenue compared to the previous year, but net profit increased, indicating improved operational efficiency. The financials show a positive cash flow and an increase in total assets, suggesting a stable financial position. However, the figures have not been audited and may be subject to adjustments, prompting caution among investors.
The most recent analyst rating on (HK:3320) stock is a Hold with a HK$5.50 price target. To see the full list of analyst forecasts on China Resources Pharmaceutical Group Ltd. stock, see the HK:3320 Stock Forecast page.
KPC Pharmaceuticals, Inc., partially owned by China Resources Pharmaceutical Group Ltd., reported a decrease in revenue and net profit for the nine months ending September 30, 2025, compared to the previous year. The financial results indicate a net decrease in cash and cash equivalents, highlighting potential challenges in liquidity. The announcement advises caution for shareholders and potential investors due to the unaudited nature of the financials, which may require adjustments.
The most recent analyst rating on (HK:3320) stock is a Hold with a HK$5.50 price target. To see the full list of analyst forecasts on China Resources Pharmaceutical Group Ltd. stock, see the HK:3320 Stock Forecast page.
Dong-E-E-Jiao, a subsidiary of China Resources Pharmaceutical Group Ltd., reported its unaudited financial results for the nine months ending September 30, 2025. The company saw an increase in revenue and net profit compared to the previous year, with revenue reaching RMB 4.77 billion and net profit at RMB 1.28 billion. Despite a decrease in total assets, the company experienced a positive net increase in cash and cash equivalents, indicating improved liquidity. Stakeholders are advised to exercise caution as the financials are unaudited and may require adjustments.
CR Double-Crane, a subsidiary of China Resources Pharmaceutical Group, reported its unaudited financial results for the nine months ending September 30, 2025. The company experienced a slight decline in revenue and net profit compared to the previous year, with revenue at RMB 8.28 billion and net profit at RMB 1.39 billion. Despite a decrease in cash and cash equivalents, the company saw an increase in total assets and owner’s equity, indicating a stable financial position. Shareholders and investors are advised to exercise caution as the financials are unaudited and may require adjustments.
Tasly Pharmaceutical reported its unaudited financial results for the nine months ending September 30, 2025, showing a slight decrease in revenue but a notable increase in net profit compared to the previous year. The financials reveal a positive cash flow change and a stable asset base, suggesting a solid financial position for Tasly, which could impact China Resources Pharmaceutical Group’s overall market standing and investor confidence.
China Resources Pharmaceutical Group Ltd. announced the successful issuance of the first tranche of its 2025 corporate bonds in China, amounting to RMB1.1 billion with a 1.82% annual coupon rate. The proceeds will be used for various operational and developmental purposes, including debt repayment and investment in scientific and technological innovations, potentially enhancing the company’s operational capabilities and market position.